Patents by Inventor Jin-Hwang Liu

Jin-Hwang Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for prolonging the over survival of a cancer patient
    Patent number: 10668093
    Abstract: The present invention relates to a method for treating a cancer with the combination of a topoisomerase II inhibitor (TOP2 inhibitor) and a histone deacetylation inhibitor (HDACi), provides synergistic cancer cell-killing effects, and prolonged overall survival, especially when the expression of checkpoint kinase 1 (CHK-1) is low.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: June 2, 2020
    Assignee: National Yang-Ming University
    Inventor: Jin-Hwang Liu
  • METHOD FOR PROLONGING THE OVER SURVIVAL OF A CANCER PATIENT
    Publication number: 20180193367
    Abstract: The present invention relates to a method for treating a cancer with the combination of a topoisomerase II inhibitor (TOP2 inhibitor) and a histone deacetylation inhibitor (HDACi), provides synergistic cancer cell-killing effects, and prolonged overall survival, especially when the expression of checkpoint kinase 1 (CHK-1) is low.
    Type: Application
    Filed: March 6, 2018
    Publication date: July 12, 2018
    Inventor: Jin-Hwang LIU
  • Method for treating a cancer
    Patent number: 9937193
    Abstract: The present invention relates to a method for treating a cancer with the combination of a topoisomerase II inhibitor (TOP2 inhibitor) and a histone deacetylation inhibitor (HDACi), provides synergistic cancer cell-killing effects, and prolonged overall survival, especially when the expression of checkpoint kinase 1 (CHK-1) is low.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: April 10, 2018
    Assignee: NATIONAL YANG-MING UNIVERSITY
    Inventor: Jin-Hwang Liu
  • METHOD FOR TREATING A CANCER
    Publication number: 20160296545
    Abstract: The present invention relates to a method for treating a cancer with the combination of a topoisomerase II inhibitor (TOP2 inhibitor) and a histone deacetylation inhibitor (HDACi), provides synergistic cancer cell-killing effects, and prolonged overall survival, especially when the expression of checkpoint kinase 1 (CHK-1) is low.
    Type: Application
    Filed: April 11, 2016
    Publication date: October 13, 2016
    Inventor: Jin-Hwang LIU
  • Promoter and viral vector containing the same
    Patent number: 8263398
    Abstract: The invention constructs an activating KRASmutant but not p53-responsive promoter and generates an E1B-55kD-deleted (?E1B-55kD) adenovirus, harboring a transcriptionally activating transgene and holding lytic replication ability in the tumor cells with activating KRASmutant. The adenovirus of the invention can be used in the treatment of cancers.
    Type: Grant
    Filed: October 19, 2010
    Date of Patent: September 11, 2012
    Inventors: Jin-Hwang Liu, Chin-Cheng Liu
  • NOVEL PROMOTER AND VIRAL VECTOR CONTAINING THE SAME
    Publication number: 20110105595
    Abstract: The invention constructs an activating KRASmutant but not p53-responsive promoter and generates an E1B-55kD-deleted (?E1B-55kD) adenovirus, harboring a transcriptionally activating transgene and holding lytic replication ability in the tumor cells with activating KRASmutant. The adenovirus of the invention can be used in the treatment of cancers.
    Type: Application
    Filed: October 19, 2010
    Publication date: May 5, 2011
    Inventors: Jin-Hwang LIU, Chin-Cheng LIU